Elevance Health vs Humana
ELV and HUM side by side, both in accident and health insurance and medical. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELV and HUM compare
Elevance Health is the larger company, worth 1.8 times as much as Humana ($93.8B against $53.2B).
On earnings, Elevance Health is cheaper: it trades at 18.5× trailing earnings, against 41.8× for Humana.
Humana grew revenue faster over the last twelve months (18.3% versus 3.6% for Elevance Health).
Elevance Health keeps more of each dollar of sales as profit, with a net margin of 2.5% compared with 0.88% at Humana.
Both pay dividends: Elevance Health yields 1.6% and Humana 0.60%.
Elevance Health scores higher on the StockData Score (15 against 9 for Humana), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELV | HUM |
|---|---|---|
| Size and price | ||
| Market cap | $93.8B | $53.2B |
| Share price | $433.93 | $443.34 |
| Change, 1 year | 33.2% | 87.0% |
| Change, 5 years | 4.4% | 3.5% |
| Beta (5Y) | 0.71 | 1.10 |
| Employees | 97K | 67K |
| StockData Score | ||
| Total score | 15 (better) | 9 |
| Valuation score | 4 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 18.5× (better) | 41.8× |
| P/S | 0.5× | 0.4× (better) |
| P/B | 2.1× (better) | 2.8× |
| EV/EBITDA | 12.9× (better) | 13.0× |
| P/FCF | 14.4× (better) | 27.3× |
| PEG | 14.68 | – |
| FCF yield | 6.9% (better) | 3.7% |
| Fair value | $487.89 | $297.30 |
| Margin of safety | 11.1% (better) | −49.1% |
| Growth | ||
| Revenue growth (TTM) | 3.6% | 18.3% (better) |
| Revenue growth, 5Y average | 10.3% | 10.9% (better) |
| Net income growth (TTM) | −7.1% (better) | −18.8% |
| EPS growth (TTM) | −4.1% (better) | −18.8% |
| EPS growth, 5Y average | 7.0% (better) | −17.2% |
| Profitability | ||
| Gross margin | 89.0% | – |
| Operating margin | 2.7% (better) | 1.9% |
| Net margin | 2.5% (better) | 0.88% |
| FCF margin | 3.2% (better) | 1.3% |
| Return on equity | 11.6% (better) | 6.8% |
| Return on invested capital | 11.0% | 23.4% (better) |
| Financial health | ||
| Debt / equity | 0.69 (better) | 0.74 |
| Net debt / EBITDA | −0.71 | −2.86 |
| Interest coverage | 3.8× | 3.8× (better) |
| Current ratio | 1.47 | 1.74 (better) |
| Altman Z-score | 3.01 | 4.66 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.6% (better) | 0.60% |
| Payout ratio | 29.2% | 33.6% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 7.8% |
| Buyback yield | 2.3% (better) | 0.28% |
| Shareholder yield | 3.9% (better) | 0.88% |
| Ownership | ||
| Held by institutions | 94.3% | 98.6% |
| Held by insiders | 0.18% | 0.32% |
| Insider net buying, 12 months | −$4.7M | −$2.4M (better) |
| Superinvestors holding | 8 (better) | 2 |
| Short interest, % of float | 2.1% | 2.3% |
Go deeper
- ELV stock overview
- ELV income statement
- ELV valuation and score
- HUM stock overview
- HUM income statement
- HUM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.